^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CD137 agonist

    Related drugs:
    16d
    SGNBB228-001: A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors (clinicaltrials.gov)
    P1, N=41, Terminated, Seagen, a wholly owned subsidiary of Pfizer | Active, not recruiting --> Terminated; The trial was terminated for strategic reasons. The decision was not based on any safety concerns.
    Trial termination
    |
    PF-08046049
    16d
    BNT314-02: A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT327) and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer (clinicaltrials.gov)
    P1/2, N=482, Recruiting, BioNTech SE | Trial completion date: May 2031 --> Dec 2032
    Trial completion date
    |
    MSI (Microsatellite instability)
    |
    Avastin (bevacizumab) • pumitamig (BNT327)
    22d
    CAB-201-005: RESET-MS: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Multiple Sclerosis (clinicaltrials.gov)
    P1/2, N=0, Withdrawn, Cabaletta Bio | N=12 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal
    |
    cyclophosphamide • fludarabine IV
    24d
    Safety and Efficacy of CTX-009 With or Without CTX-471 for Recurrent Glioblastoma (clinicaltrials.gov)
    P1/2, N=54, Recruiting, Washington University School of Medicine | Not yet recruiting --> Recruiting
    Enrollment open
    |
    IDH wild-type
    |
    tovecimig (CTX-009)
    25d
    Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing (clinicaltrials.gov)
    P3, N=77, Active, not recruiting, Pfizer | Trial completion date: Sep 2026 --> Dec 2026 | Trial primary completion date: Sep 2026 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    Bavencio (avelumab) • Talzenna (talazoparib) • pemetrexed • axitinib • vidutolimod (CMP-001) • utomilumab (PF-05082566) • ivuxolimab (PF-04518600)
    1m
    A Study of PRS-344/S095012 (PD-L1x4-1BB Bispecific Antibody) in Patients With Solid Tumors (clinicaltrials.gov)
    P1/2, N=46, Terminated, Servier Bio-Innovation LLC | Completed --> Terminated; Sponsor decision to terminate during Phase 1
    Trial termination • First-in-human
    1m
    Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07) (clinicaltrials.gov)
    P2, N=1, Terminated, Genmab | Trial completion date: Jul 2029 --> May 2026 | Active, not recruiting --> Terminated | Trial primary completion date: Jul 2027 --> May 2026; Genmab has decided to discontinue further clinical development of acasunlimab following strategic portfolio prioritization. The decision was not related to safety concerns.
    Trial completion date • Trial termination • Trial primary completion date • Checkpoint inhibition
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation • BRAF V600
    |
    Keytruda (pembrolizumab) • acasunlimab (GEN1046)
    1m
    FTL008.16, a 5T4-Conditional 4-1BB bispecific antibody, potently enhances antitumor immunity via tumor-directed t-cell activation. (PubMed, Oncoimmunology)
    Importantly, this 5T4-restricted activation mechanism confines immune stimulation to the tumor microenvironment, thereby circumventing the systemic toxicity associated with conventional 4-1BB agonists. Collectively, these findings establish FTL008.16 as a conditionally active immunotherapeutic agent that successfully achieves both robust antitumor efficacy and a favorable safety profile.
    Journal
    |
    TNFRSF9 (TNF Receptor Superfamily Member 9)
    2ms
    A Study of LVGN6051 Combined With Anlotinib in Patient With Soft Tissue Sarcoma (clinicaltrials.gov)
    P1/2, N=39, Completed, Lyvgen Biopharma Holdings Limited | Recruiting --> Completed | N=65 --> 39 | Trial primary completion date: Mar 2025 --> Dec 2025
    Trial completion • Enrollment change • Trial primary completion date • IO biomarker
    |
    Focus V (anlotinib) • exlinkibart (LVGN6051)
    2ms
    Phase 1 Trial of LVGN7409 (CD40 Agonist Antibody) as Single Agent and Combination Therapies in Advanced or Metastatic Malignancy (clinicaltrials.gov)
    P1, N=66, Completed, Lyvgen Biopharma Holdings Limited | Active, not recruiting --> Completed | N=126 --> 66
    Trial completion • Enrollment change • First-in-human
    |
    dalnicastobart (LVGN7409) • exlinkibart (LVGN6051) • pradusinstobart (LVGN3616)
    2ms
    A Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC) (clinicaltrials.gov)
    P2, N=64, Active, not recruiting, Lyvgen Biopharma Holdings Limited | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    paclitaxel • Loqtorzi (toripalimab-tpzi) • exlinkibart (LVGN6051)
    2ms
    KEYNOTE-A31: Phase 1 Trial of LVGN6051 as Single Agent and in Combination With Keytruda (Pembrolizumab) in Advanced or Metastatic Malignancy (clinicaltrials.gov)
    P1, N=105, Completed, Lyvgen Biopharma Holdings Limited | Active, not recruiting --> Completed | N=276 --> 105
    Trial completion • Enrollment change • First-in-human
    |
    Keytruda (pembrolizumab) • exlinkibart (LVGN6051)